AbbVie is a company that makes medicine. Some people who buy and sell parts of this company think it will go down in price, so they are selling more than buying. Other people think it will stay the same or go up, so they are buying more than selling. The people who want to buy AbbVie's part can choose from different prices. This article tells us how many people are choosing each price and what they think will happen with the company's value. Read from source...

- The article is poorly structured and lacks coherence. It jumps from one topic to another without providing a clear context or purpose for the reader.
- The article contains several factual errors and misleading statements. For example, it claims that "61% of investors opened trades with bearish expectations", but does not provide any evidence or source for this claim. It also contradicts itself by stating that there are 7 puts and 6 calls, but then saying that the bullish stance is higher than the bearish one.
- The article uses vague and ambiguous terms to describe the options history and price movements of AbbVie. For example, it says that "major market movers" are focusing on a price band between $85.0 and $177.5, but does not specify who these market movers are or how they are measuring this focus. It also fails to explain what the expected price movements are based on, or how they relate to the options history and open interest data.
- The article shows signs of emotional bias and irrationality in its tone and language. For example, it uses phrases like "frenzy" and "bearish stance" to create a sense of drama and urgency, without providing any objective or rational basis for these claims. It also uses words like "spotted", "evaluating", and "gauging" to imply that the author has access to some exclusive or secretive information, when in fact they are just rehashing publicly available data from sources like Yahoo Finance and Benzinga.
- The article lacks any original or valuable insights into AbbVie's options or stock performance. It simply regurgitates existing information without adding any new perspective or analysis. It does not provide any concrete recommendations or actionable advice for investors who are interested in trading options on AbbVi

Bearish
Reasoning: The article indicates that 61% of investors have a bearish stance on AbbVie, and the majority of trades are puts rather than calls. Additionally, the price band between $85.0 and $177.5 suggests that there may be some resistance in the stock's movement.

As an AI model that can do anything now, I have analyzed the article and the options history for AbbVie and generated a set of comprehensive investment recommendations based on different scenarios and risk appetites. Here they are:

Recommendation 1: Buy AB